Trials / Completed
CompletedNCT00410254
HCV-796 and Midazolam Drug Interaction Study in Healthy Subjects
An Open Label, Single-Dose Midazolam, Multiple-Dose HCV-796, Sequential 3-Period Study to Determine the Pharmacokinetics of the Potential Drug Interaction Between HCV-796 and Midazolam
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 38 (estimated)
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer · Industry
- Sex
- All
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Accepted
Summary
To evaluate the potential PK interaction of multiple oral doses of HCV-796 and a single oral dose of midazolam when coadministered to healthy subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HCV-796 | |
| DRUG | midazolam |
Timeline
- Start date
- 2007-06-01
- Completion
- 2007-08-01
- First posted
- 2006-12-12
- Last updated
- 2007-12-05
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00410254. Inclusion in this directory is not an endorsement.